The Federal Reserve is grappling with elevated inflation by taking a hawkish stance and raising interest rates. Sprinkle in solid growth companies whose stock has fallen out of favor, yet for which the secular bull case remains intact.
AbbVie (ABBV) closed the most recent trading day at $153.93, moving +0.08% from the previous trading session.
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.